OVERCOMING DRUG SOLUBILITY CHALLENGES
Catalent Presents Drug Delivery Strategies at 7th Annual Improving Solubility Conference in Philadelphia
SOMERSET, NJ, February 25, 2013 – Norman Stroud, Director of Technology Development at Catalent Pharma Solutions, is to present “Strategies to overcome drug solubility challenges utilizing advances in gelatin and OptiShell® soft capsule technologies" at IQPC’s 7th Annual Improving Solubility Conference at 5:00pm on Wednesday Feb 27, 2013.
Mr. Stroud’s presentation will include an overview of soft capsule technologies including conventional gelatin-based capsule shells and Catalent’s proprietary OptiShell technology. It will highlight the many advantages of using RP Scherer softgels for the encapsulation of drugs solubilized in hydrophilic vehicles, and include a review of lipid-based fill formulations such as self-emulsifying and self-micro emulsifying drug delivery systems (SEDDS and SMEDDS). Mr. Stroud will also discuss recent advances and developments in overcoming solubility challenges using polysaccharide-based soft capsule shells.
Mr. Stroud has led the development of the innovative, Vegicaps® and OptiShell soft capsule technologies at Catalent. Mr. Stroud began his career working in the Pharmaceutics Department, School of Pharmacy and Pharmacology, University of Bath, England. During his time in academia, Mr. Stroud held various positions in pharmaceutical research and development, with a focus on the development of liquid dosage forms. Mr. Stroud received his B.Sc (Hons) degree in Biochemistry from Cardiff University, Wales, and has been granted eight US patents.
Catalent RP Scherer softgel, embodies more than 75 years of development expertise and manufacturing experience applicable to the full spectrum of drug delivery. Softgel is the drug delivery solution of choice that solves complex formulation, solubility, bioavailability, and development challenges, bringing more molecules to market faster.
IQPC’s 7th Annual Improving Solubility Conference will showcase the newest solubility technologies and provide the latest research from established industry leaders, providing practical, applicable knowledge to effectively improve bioavailability and drug candidate solubility. The conference runs from February 26, 2013 for three days at The HUB Commerce Square, Philadelphia, Pennsylvania. For more information visit www.improvingsolubility.com
To learn more about Catalent’s RP Scherer and OptiShell drug delivery technology please visit www.catalent.com
Catalent Pharma Solutions is the global leader in development solutions and advanced drug delivery technologies, providing world-wide clinical and commercial supply capabilities for drugs, biologics and consumer health products. With over 75 years serving the industry, Catalent has proven expertise in bringing more products to market faster, enhancing product performance and ensuring reliable product supply. Catalent employs approximately 9,000 people, including over 1,000 scientists, at nearly 30 facilities across 5 continents and generates more than $1.6 billion in annual revenue. Catalent is headquartered in Somerset, NJ. For more information, visit www.catalent.com.